Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.

@article{Lu2011OutcomesOS,
  title={Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.},
  author={Ching-Lan Lu and Yu-hui Lin and W Wong and H Lin and M Ho and N Wang and S M Hsieh and W M Sheng and Chien-Ching Hung and Mao-Yuan Chen},
  journal={Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi},
  year={2011},
  volume={44 4},
  pages={258-64}
}
BACKGROUND Prolonged exposure to combination antiretroviral therapy (CART) may result in hyperlipidemia and other metabolic complications. This study aimed to evaluate the clinical, virologic, and immunologic outcomes in HIV-infected patients with hyperlipidemia whose CART was switched to atazanavir-containing antiretroviral regimens. METHODS In this 48-week prospective, observational study that was conducted at designated hospitals for HIV care in Taiwan, HIV-infected patients aged 18 years… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 44 references

Short-term effect of ritonavir-boosted ataza- navir in hepatitis B and/or C co-infected, treatment-experi- enced HIV patients

MJ Pérez-Elı́as, JM Gatell, +3 authors B Clotet
HIV Clin Trials 2009;10:269e75 • 2009
View 1 Excerpt

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with unde- tectable plasma viraemia: final results of the SLOAT trial

V Soriano, P Garcı́a-Gasco, +3 authors L Martı́n-Carbonero
J Antimicrob Chemother 2008;61:200e5 • 2008
View 2 Excerpts

Similar Papers

Loading similar papers…